Difference between revisions of "Category:Protein expression-specific medications"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
 
Line 1: Line 1:
−
Drugs with an FDA indication for effectiveness (or lack of efficacy) in the context of one or more measurable protein expression patterns (including the absence of a protein expression, e.g., triple-negative breast cancer).
+
Drugs with a regulatory indication for effectiveness (or lack of efficacy) in the context of one or more measurable protein expression patterns (including the absence of a protein expression, e.g., triple-negative breast cancer). This also includes mismatch repair deficient (dMMR) indications.
  
 
[[Category:Biomarker-specific medications]]
 
[[Category:Biomarker-specific medications]]

Latest revision as of 00:29, 15 June 2024

Drugs with a regulatory indication for effectiveness (or lack of efficacy) in the context of one or more measurable protein expression patterns (including the absence of a protein expression, e.g., triple-negative breast cancer). This also includes mismatch repair deficient (dMMR) indications.

Retrieved from "https://hemonc.org/w/index.php?title=Category:Protein_expression-specific_medications&oldid=86215"